financetom
Business
financetom
/
Business
/
US senator introduces bill calling for location-tracking on AI chips to limit China access
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US senator introduces bill calling for location-tracking on AI chips to limit China access
May 26, 2025 5:10 AM

(Reuters) -A U.S. senator introduced a bill on Friday that would direct the Commerce Department to require location verification mechanisms for export-controlled AI chips, in an effort to curb China's access to advanced semiconductor technology.

Called the "Chip Security Act," the bill calls for AI chips under export regulations, and products containing those chips, to be fitted with location-tracking systems to help detect diversion, smuggling or other unauthorized use of the product.

"With these enhanced security measures, we can continue to expand access to U.S. technology without compromising our national security," Republican Senator Tom Cotton of Arkansas said.

The bill also calls for companies exporting the AI chips to report to the Bureau of Industry and Security if their products have been diverted away from their intended location or subject to tampering attempts.

The move comes days after U.S. President Donald Trump said he would rescind and modify a Biden-era rule that curbed the export of sophisticated AI chips with the goal of protecting U.S. leadership in AI and blocking China's access.

U.S. Representative Bill Foster, a Democrat from Illinois, also plans to introduce a bill on similar lines in the coming weeks, Reuters reported on Monday.

Restricting China's access to AI technology that could enhance its military capabilities has been a key focus for U.S. lawmakers and reports of widespread smuggling of Nvidia's chips into China in violation of export control laws have further amplified the concerns.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Thoughtworks Holding Q3 Adjusted Earnings, Revenue Fall
Thoughtworks Holding Q3 Adjusted Earnings, Revenue Fall
Nov 12, 2024
09:06 AM EST, 11/12/2024 (MT Newswires) -- Thoughtworks Holding ( TWKS ) reported Q3 adjusted earnings Tuesday of $0.03 per diluted share, down from $0.04 a year earlier. Analysts polled by Capital IQ expected $0.03. Revenue for the quarter ended Sept. 30 was $261.4 million, down from $280.2 million a year earlier. Analysts surveyed by Capital IQ expected $256.5 million....
BRIEF-Cadiz To Purchase 180 Miles Of New Pipeline Assets
BRIEF-Cadiz To Purchase 180 Miles Of New Pipeline Assets
Nov 12, 2024
Nov 12 (Reuters) - Cadiz Inc ( CDZI ): * CADIZ TO PURCHASE 180 MILES OF NEW PIPELINE ASSETS * CADIZ INC ( CDZI ) - TO PURCHASE 180 MILES OF STEEL PIPE FROM KEYSTONE XL * CADIZ INC ( CDZI ) - TO BEGIN PIPELINE CONSTRUCTION IN 2025 Source text: Further company coverage: ...
Endava's Fiscal Q1 Adjusted Earnings Fall, Revenue Rises; Fiscal Q2 Guidance Issued
Endava's Fiscal Q1 Adjusted Earnings Fall, Revenue Rises; Fiscal Q2 Guidance Issued
Nov 12, 2024
08:57 AM EST, 11/12/2024 (MT Newswires) -- Endava ( DAVA ) reported fiscal Q1 adjusted earnings Tuesday of 0.25 British pounds ($0.32) per diluted share, down from 0.39 pounds a year earlier. Analysts polled by Capital IQ expected 0.21 pounds. Revenue for the quarter ended Sept. 30 was 195.1 million pounds, up from 188.4 million pounds a year earlier. Analysts...
US FDA declines full approval for Intercept's liver disease drug
US FDA declines full approval for Intercept's liver disease drug
Nov 12, 2024
By Bhanvi Satija and Puyaan Singh Nov 12 (Reuters) - The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, raising questions about its future in the market. The drug, Ocaliva, will continue to be available in the U.S. under the accelerated approval status, the company said. Under the accelerated pathway, the FDA...
Copyright 2023-2026 - www.financetom.com All Rights Reserved